Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

142 results
  1. ... kidney... Article: Effects of two immunosuppression regimens on T-lymphocyte subsets in elderly kidney... Kidney Transplantation -- see more articles Reference Desk Kidneys and Urinary Tract (For Parents) (Nemours ...
  2. ... pathogenic variants in STAT3 occur most frequently in T-cell large granular lymphocyte leukemia [ Koskela et al 2012 ]. Somatic ... Cited Arora M, Bagi P, Strongin A, ...
  3. ... evidence for circulating Sézary cells is provided by T-cell receptor gene analysis, identification of the atypical ... Olsen EA, Rook AH, Zic J, et al.: ...
  4. ... Taguchi H, Yoshimoto S, et al. Inactivation of lymphocyte-transforming activity of human T-cell leukemia virus type I by heat. Japanese Journal of Cancer Research. 1986; 77 :13–5. [ PubMed : 3007413 ] Excluded studies 323 references were excluded at the full-text stage. Human ...
  5. ... can be elevated in any condition in which T-cell activation is present. Because ... by cytotoxic lymphocytes to kill target cells. Increased expression of granzyme ...
  6. ... by other organizations, see the ClinicalTrials.gov website . References ... Blood 105 (5): 1898-904, 2005. [ PubMed : 15542583 ] ...
  7. ... General information about clinical trials is also ... and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal ...
  8. ... HL. Lymphocyte-rich classical HL. Mixed-cellularity ... Treatment References Zeppa P, Marino G, Troncone G, et al.: ...
  9. ... HL. Lymphocyte-rich classical HL. Mixed-cellularity ... Treatment References Zeppa P, Marino G, Troncone G, et al.: ...
  10. ... until disease progression or intolerable toxicity. Anti–cytotoxic T-lymphocyte antigen-4 (CTLA-4) Ipilimumab Ipilimumab is a human monoclonal antibody that binds to CTLA-4, thereby blocking its ability to downregulate T-cell activation, proliferation, and effector function. Approved by the ...
first · previous · 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · next · last